Needham analyst Michael Matson reiterated a Buy rating on Masimo Corp (MASI) on August 1 and set a price target of $182. The company’s shares closed on Friday at $151.51, close to its 52-week high of $160.25.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 8.6% and a 65.3% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Merit Medical Systems.
Currently, the analyst consensus on Masimo Corp is a Strong Buy with an average price target of $169, implying an 11.5% upside from current levels. In a report issued on August 1, Piper Jaffray also maintained a Buy rating on the stock with a $168 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $160.25 and a one-year low of $98.23. Currently, Masimo Corp has an average volume of 419.7K.
Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MASI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Masimo Corp. is a medical technology company, which develops, manufactures and markets non invasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories.
